Results 81 to 90 of about 861,766 (382)

Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: systematic review and meta-regression [PDF]

Multiple Sclerosis Journal, 19(12):1580-1586, 2013, 2013
Background: Recent studies have shown a decrease in annualised relapse rates (ARRs) in placebo groups of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS). Methods: We conducted a systematic literature search of RCTs in RMS.
arxiv   +1 more source

Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice. [PDF]

, 2019
Bladder cancer is among the top ten most common cancers, with about ~380,000 new cases and ~150,000 deaths per year worldwide. Tumor relapse following chemotherapy treatment has long been a significant challenge towards completely curing cancer.
de Vere White, Ralph, Ghosh, Paramita M, He, Wei, Hum, Nicholas R, Loots, Gabriela G, Martin, Kelly A, Pan, Chong-Xian, Sebastian, Aimy, Siddiqui, Salma   +8 more
core   +2 more sources

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

Identification of Master Regulators Driving Disease Progression, Relapse, and Drug Resistance in Lung Adenocarcinoma

Frontiers in Bioinformatics, 2022
Backgrounds: Lung cancer is the leading cause of cancer related death worldwide. Current treatment strategies primarily involve surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, determined by TNM stages, histologic types, and ...
Qiong Xu, Qiongfang Cha, Hui Qin, Bin Liu, Xueling Wu, Jiantao Shi   +5 more
doaj   +1 more source

Ex vivo innate immune cytokine signature of enhanced risk of relapsing brucellosis. [PDF]

, 2013
BackgroundBrucellosis, a zoonotic infection caused by one of the Gram-negative intracellular bacteria of the Brucella genus, is an ongoing public health problem in Perú.
Feldman, Kristyn E, Gilman, Robert H, Gotuzzo, Eduardo, Hoffmann, Alexander, Loriaux, Paul M, Saito, Mayuko, Siva, Tenaya, Tuero, Iskra, Villaverde, Homarh, Vinetz, Joseph M   +9 more
core   +3 more sources

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

The Role of Nonlinear Relapse on Contagion Amongst Drinking Communities [PDF]

arXiv, 2020
Relapse, the recurrence of a disorder following a symptomatic remission, is a frequent outcome in substance abuse disorders. Some of our prior results suggested that relapse, in the context of abusive drinking, is likely an "unbeatable" force as long as recovered individuals continue to interact in the environments that lead to and/or reinforce the ...
arxiv  

Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. [PDF]

, 2016
OBJECTIVE: To study rituximab in pediatric neuromyelitis optica (NMO)/NMO spectrum disorders (NMOSD) and the relationship between rituximab, B cell repopulation, and relapses in order to improve rituximab monitoring and redosing.
Alper, G, Appleton, R, Banwell, B, Benson, La, Brilot, F, Dale, R. C., Deiva, K, Gorman, Mp, Leventer, Rj, Mohammad, Ss, Nolan, M, Nosadini, M, Ramanathan, S, Riney, Cj, Waldman, At   +14 more
core   +1 more source

Management of Relapsed and Relapsed/Refractory Multiple Myeloma [PDF]

Journal of the National Comprehensive Cancer Network, 2011
Despite significant progress in the treatment of multiple myeloma (MM) over the past decade, this disease remains incurable and almost all patients ultimately experience relapse and become refractory to treatment over time. However, the outlook for patients with relapsed MM has improved markedly with the use of the immunomodulatory drugs thalidomide ...
Nikhil C. Munshi, Paul G. Richardson, Jacalyn Rosenblatt, Kenneth C. Anderson, David Avigan, Robert L. Schlossman, Noopur Raje, Irene M. Ghobrial, Constantine S. Mitsiades, Anuj Mahindra, Marlise R. Luskin, Jacob P. Laubach   +11 more
openaire   +3 more sources

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source